May 05, 2013 - 1:20 am
IS ANYONE PARTICIPATING IN THIS TRIAL?
This trial sounds very promising. It combines two experimental drugs, the much-sought-after PD-1 drug BMS-936558 (nivolumab) and an anti-KIR drug BMS-986015. This trial is available to qualified patients with colorectal cancer, kidney cancer, melanoma, NSCLC (non-small cell lung cancer), and ovarian cancer. The trial is underway in Baltimore, Chicago, and New York.
Note: This trial is not yet recruiting in Boston or Portland.